Literature DB >> 27358497

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Yosi Shamay1, Moshe Elkabets2, Hongyan Li3, Janki Shah1, Samuel Brook4, Feng Wang5, Keren Adler6, Emily Baut7, Maurizio Scaltriti8, Prakrit V Jena1, Eric E Gardner9, John T Poirier10, Charles M Rudin10, José Baselga11, Adriana Haimovitz-Friedman3, Daniel A Heller12.   

Abstract

Disseminated tumors are poorly accessible to nanoscale drug delivery systems because of the vascular barrier, which attenuates extravasation at the tumor site. We investigated P-selectin, a molecule expressed on activated vasculature that facilitates metastasis by arresting tumor cells at the endothelium, for its potential to target metastases by arresting nanomedicines at the tumor endothelium. We found that P-selectin is expressed on cancer cells in many human tumors. To develop a targeted drug delivery platform, we used a fucosylated polysaccharide with nanomolar affinity to P-selectin. The nanoparticles targeted the tumor microenvironment to localize chemotherapeutics and a targeted MEK (mitogen-activated protein kinase kinase) inhibitor at tumor sites in both primary and metastatic models, resulting in superior antitumor efficacy. In tumors devoid of P-selectin, we found that ionizing radiation guided the nanoparticles to the disease site by inducing P-selectin expression. Radiation concomitantly produced an abscopal-like phenomenon wherein P-selectin appeared in unirradiated tumor vasculature, suggesting a potential strategy to target disparate drug classes to almost any tumor.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27358497      PMCID: PMC5064151          DOI: 10.1126/scitranslmed.aaf7374

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  57 in total

Review 1.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

2.  Role of ICAM1 in invasion of human breast cancer cells.

Authors:  Caridad Rosette; Richard B Roth; Paul Oeth; Andreas Braun; Stefan Kammerer; Jonas Ekblom; Mikhail F Denissenko
Journal:  Carcinogenesis       Date:  2005-03-17       Impact factor: 4.944

3.  Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure.

Authors:  K S Mark; D W Miller
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

4.  Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.

Authors:  M Verheij; R Bose; X H Lin; B Yao; W D Jarvis; S Grant; M J Birrer; E Szabo; L I Zon; J M Kyriakis; A Haimovitz-Friedman; Z Fuks; R N Kolesnick
Journal:  Nature       Date:  1996-03-07       Impact factor: 49.962

5.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

Review 6.  Deadly allies: the fatal interplay between platelets and metastasizing cancer cells.

Authors:  Luise Erpenbeck; Michael P Schön
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

7.  Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Authors:  Jeffrey Hrkach; Daniel Von Hoff; Mir Mukkaram Ali; Elizaveta Andrianova; Jason Auer; Tarikh Campbell; David De Witt; Michael Figa; Maria Figueiredo; Allen Horhota; Susan Low; Kevin McDonnell; Erick Peeke; Beadle Retnarajan; Abhimanyu Sabnis; Edward Schnipper; Jeffrey J Song; Young Ho Song; Jason Summa; Douglas Tompsett; Greg Troiano; Tina Van Geen Hoven; Jim Wright; Patricia LoRusso; Philip W Kantoff; Neil H Bander; Christopher Sweeney; Omid C Farokhzad; Robert Langer; Stephen Zale
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

8.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

9.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  48 in total

Review 1.  Advances in the clinical translation of nanotechnology.

Authors:  David A Scheinberg; Jan Grimm; Daniel A Heller; Evan P Stater; Michelle Bradbury; Michael R McDevitt
Journal:  Curr Opin Biotechnol       Date:  2017-02-07       Impact factor: 9.740

2.  Photosensitization Priming of Tumor Microenvironments Improves Delivery of Nanotherapeutics via Neutrophil Infiltration.

Authors:  Dafeng Chu; Xinyue Dong; Qi Zhao; Jingkai Gu; Zhenjia Wang
Journal:  Adv Mater       Date:  2017-05-15       Impact factor: 30.849

3.  Targeted therapies: P-selectin guides nanoparticle delivery to tumours.

Authors:  Peter Sidaway
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

4.  Cancer Immunotherapy: From local to global.

Authors:  Willem J M Mulder; Sacha Gnjatic
Journal:  Nat Nanotechnol       Date:  2017-09-06       Impact factor: 39.213

Review 5.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.

Authors:  John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2020-02-07       Impact factor: 66.675

6.  Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44.

Authors:  Deep S Bhattacharya; Denis Svechkarev; Aishwarya Bapat; Prathamesh Patil; Michael A Hollingsworth; Aaron M Mohs
Journal:  ACS Biomater Sci Eng       Date:  2020-05-04

Review 7.  Integrating nanomedicine into clinical radiotherapy regimens.

Authors:  Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas; Conroy Sun
Journal:  Adv Drug Deliv Rev       Date:  2019-07-04       Impact factor: 15.470

8.  The Effect of Cage Shape on Nanoparticle-Based Drug Carriers: Anticancer Drug Release and Efficacy via Receptor Blockade Using Dextran-Coated Iron Oxide Nanocages.

Authors:  Sham Rampersaud; Justin Fang; Zengyan Wei; Kristina Fabijanic; Stefan Silver; Trisha Jaikaran; Yuleisy Ruiz; Murielle Houssou; Zhiwei Yin; Shengping Zheng; Ayako Hashimoto; Ayuko Hoshino; David Lyden; Shahana Mahajan; Hiroshi Matsui
Journal:  Nano Lett       Date:  2016-11-10       Impact factor: 11.189

9.  One-pot synthesis of nanochain particles for targeting brain tumors.

Authors:  V S Perera; G Covarrubias; M Lorkowski; P Atukorale; A Rao; S Raghunathan; R Gopalakrishnan; B O Erokwu; Y Liu; D Dixit; S M Brady-Kalnay; D Wilson; C Flask; J Rich; P M Peiris; E Karathanasis
Journal:  Nanoscale       Date:  2017-07-13       Impact factor: 7.790

Review 10.  Selectins in cancer immunity.

Authors:  Lubor Borsig
Journal:  Glycobiology       Date:  2018-09-01       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.